Pay with Crypto and get 10% off your order!
Use: This test is used for measurement of glial fibrillary acidic protein (GFAP) in EDTA plasma.
Limitations: This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
There are significant variations in measured GFAP levels among different methods and labs. Care must be taken when interpreting results obtained in different studies.
Given the frequent occurrence of mixed brain pathologies in dementia,1 the assessment of biomarker accuracy should account for the effect of overlapping comorbidities.
GFAP levels have low specificity for differentiating among stroke subtypes.2
Along with neural astrocytes, small amounts of GFAP are expressed in the periphery by Schwann cells, mature glial cells in the gut, hepatic stellate cells and other non-neural cells.3,4
Methodology: Roche Diagnostics Electrochemiluminescence Immunoassay (ECLIA)
